In fact, CML is a myeloprolifelative disorder that is caused by the BCR-ABL oncogene and DAS is a potent inhibitor of imatinib-resistant BCR-ABL mutants [2,3]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.